Long-term study of children with immune thrombocytopenia
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 17 years old.
- You have been diagnosed with immune thrombocytopenia (ITP), a condition where your body destroys platelets too quickly.
- Your low platelet count is not caused by another health problem like a blood or immune disorder, cancer, or certain medications.
- You can be followed for at least 3 months as part of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
This trial tests an experimental oral medication called TQB3473 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets causing low counts and bleeding risk. The goal is to see if the drug can safely improve platelet counts and reduce bleeding symptoms.
This study follows people who have immune thrombocytopenia (ITP), a condition where the blood doesn't clot properly because of low platelets. By tracking patients over time, researchers hope to learn more about the disease and how it affects people.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.